NCT04926831 2025-10-16
Geometry-N
Novartis
Phase 2 Terminated
Clinical Trials
3 trialsNCT05243641 2025-06-11
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated